855249-68-2

Upstream product

• 459-46-1 4-Fluorobenzyl bromide 
• 459-57-4 4-fluorobenzaldehyde 
• 1535-41-7 1-fluoro-4-(nitromethyl)benzene 
• 855248-37-2 3,4-bis-(4-fluorophenyl)-5-formyl-1-isopropyl-1H-pyrrole-2-carboxylic acid ethyl ester 
• 126209-33-4 3,4-bis-(4-fluorophenyl)-1-isopropyl-1H-pyrrole-2-carboxylic acid ethyl ester 
• 126209-32-3 3,4-bis-(4-fluorophenyl)-1H-pyrrole-2-carboxylic acid ethyl ester 
• 855248-38-3 3,4-bis-(4-fluoro-phenyl)-5-formyl-1-isopropyl-1H-pyrrole-2-carboxylic acid 

Downstream Products

• 950599-02-7 C₄₃H₅₁F₂N₃O₆Si 
• 950599-55-0 C₃₇H₃₇F₂N₃O₆ 
• 855249-74-0 trans (3R,5S)-7-[5-(3-dimethylcarbamoylphenylcarbamoyl)-3,4-bis-(4-fluorophenyl)-1-isopropyl-1H-pyrrolyl]-3,5-dihydroxyhept-6-enoic acid methyl ester 
• 855249-76-2 (3R,5R)-7-[5-(3-dimethylcarbamoylphenylcarbamoyl)-3,4-bis-(4-fluorophenyl)-1-isopropyl-1H-pyrrolyl]-3,5-dihydroxyheptanoic acid methyl ester 

Relevant academic research and scientific papers

Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors

This manuscript describes the design and synthesis of a series of pyrrole-based inhibitors of HMG-CoA reductase for the treatment of hypercholesterolemia. Analogs were optimized using structure-based design and physical property considerations resulting i